We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Immunofluorescence Assay Developed for Hantaviruses

By LabMedica International staff writers
Posted on 15 Apr 2013
Simultaneous tests were developed for clinically important Old and New World hantaviruses using multiparametric indirect immunofluorescence assays (IFAs) based on biochip mosaics. More...


To detect serum antibodies each of the mosaic substrates consisted of cells infected with one of the virus types Hantaan (HTNV), Puumala (PUUV), Seoul (SEOV), Saaremaa (SAAV), Dobrava (DOBV), Sin Nombre (SNV) or Andes (ANDV).

Scientists from the Euroimmun Medizinische Labordiagnostika AG, ( Luebeck, Germany) in collaboration with others, analyzed 184 laboratory-confirmed Hantavirus-positive sera collected at six diagnostic centers from patients actively or previously infected with different Hantavirus serotypes. The control panel comprised 89 sera from healthy blood donors. The Euroimmun’s Hantavirus Mosaic 1 and 3 were used for the multiparametric IFA-based detection of Hantavirus-specific immunoglobulin G (IgG) and IgM.

The overall qualitative performance of multiparametric IFAs in detecting anti-Hantavirus antibodies was analyzed by considering those samples as seropositive that showed specific reactivity with a cut-off 1:100, against at least one of the different Hantavirus serotypes contained in the biochip mosaics. In the multiparametric IFA applied in the study, 99% of the patient sera were IgG positive and 71% were IgM positive. Overall IFA sensitivity for combined IgG and IgM analysis amounted to 100% for all serotypes, except for SNV, which was 96%. Of the 89 control sera, 2% showed IgG reactivity against the HTNV substrate, but not against any other Hantavirus.

The authors concluded that analysis of Hantavirus-specific IgG and IgM by indirect immunofluorescence on substrate mosaics consisting of cells infected with different hantaviruses is a globally applicable. The method is a reliable diagnostic tool for screening of patients suspected of having Hantavirus infection, and can be useful for serotyping in areas where hantaviruses of different serogroups are endemic. The multiparametric IFA enables highly sensitive and specific serological diagnosis of Hantavirus infections and can be used to differentiate PUUV and ANDV infection from infections with Murinae-borne hantaviruses such as DOBV and SEOV. The study was published on April 4, 2013, in the journal Public Library of Science Neglected Tropical Diseases.

Related Links:
Euroimmun Medizinische Labordiagnostika AG



Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Automatic Hematology Analyzer
CF9600
New
Fully Automated Urinalysis System
DxU 1800 Fully Automated Urinalysis System
New
Next-Generation Sequencing Platform
AXELIOS 1 Platform
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Tracking blood test trends alongside unexplained weight loss may help identify patients at increased cancer risk and support earlier investigation (Image Credit: 123RF)

Blood Test Patterns Improve Cancer Risk Assessment in Primary Care

Unexplained weight loss is a common but nonspecific presentation in primary care that can precede several types of cancer, making referral decisions difficult. Routine blood tests may produce borderline... Read more

Molecular Diagnostics

view channel
Image: NTM are about 200 environmental bacteria found in soil and water that can cause chronic, tuberculosis-like lung infections but are distinct from the Mycobacterium tuberculosis complex (Image Credit: Adobe Stock)

Rapid CRISPR Test Identifies Nontuberculous Mycobacteria Species from Respiratory Samples

Chronic lung infections caused by nontuberculous mycobacteria (NTM) are increasingly recognized but frequently mistaken for tuberculosis, complicating diagnosis and care. These infections may affect as... Read more

Immunology

view channel
Image: Although many people harbor latent Epstein-Barr virus (EBV), growing evidence has linked the virus to MS pathobiology (Image Credit: Adobe Stock)

Blood EBV Activity Biomarkers May Predict Multiple Sclerosis Relapse Months Ahead

Predicting relapse in multiple sclerosis (MS) remains difficult, limiting opportunities for timely intervention and monitoring. Although many people harbor latent Epstein-Barr virus (EBV), growing evidence... Read more

Pathology

view channel
Image Credit: Adobe Stock

Machine Learning Cytology Tool Improves Cancer Cell Identification

Cytological screening remains central to early cancer detection, but its accuracy depends heavily on expert interpretation of stained cells. Under conventional microscopy, malignant and reactive cells... Read more

Technology

view channel
Image: ADLM recommends that emerging AI tools follow the same professional oversight, quality, validation, and monitoring standards as traditional clinical testing within CLIA’s existing framework (Image Credit: Adobe Stock)

ADLM Calls for CLIA Updates to Support Safe AI Use in Laboratory Medicine

Clinical laboratories increasingly use artificial intelligence to verify, interpret, and report results, but safeguards under the Clinical Laboratory Improvement Amendments (CLIA) were designed in 1992.... Read more

Industry

view channel
Image: The acquisition adds Convergent Genomics’ UroAmp platform and proprietary urinary tumor DNA technology to Veracyte’s portfolio (Photo courtesy of Convergent Genomics)

Veracyte Acquisition Expands Urine-Based Bladder Cancer Monitoring Capabilities

Veracyte, Inc. has acquired Convergent Genomics, expanding its urology diagnostics offerings with the company’s UroAmp platform and proprietary urinary tumor DNA (utDNA) technology. UroAmp has been clinically... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.